San Diego, CA - Dec. 8, 2003 -TargeGen, Inc., a biotechnology company focusing on cardiovascular (ischemic) diseases and cancer, today announced the appointment of Ray Gibbons, M.D., to its Scientific Advisory Board.

Dr. Gibbons currently serves as The Arthur M. and Gladys D. Gary Professor of Medicine at Mayo Clinic (Rochester, MN) where he specializes in cardiovascular disease. Dr. Gibbons serves on the Editorial Boards of several major journals in the field of cardiovascular medicine and imaging. He has published more than 240 articles in peer reviewed scientific journals. Dr. Gibbons received his B.S.E. from Princeton University, M.Sc. from Oxford, and M.D. from Harvard Medical School. "We are extremely pleased to have someone of Dr. Gibbons's stature in the field of cardiovascular medicine join our Scientific Advisory Board," said Peter G. Ulrich, President and CEO of TargeGen. "TargeGen will certainly benefit from his well recognized expertise in cardiology and cardiovascular imaging as we advance our compound to treat acute myocardial infarction into human clinical trials."

About TargeGen, Inc.

TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company based in San Diego, CA. TargeGen is developing novel small molecule therapeutics to treat cancer and ischemic diseases (heart attack, stroke) by targeting certain biochemical processes associated with the formation and repair of blood vessels and vascular permeability (VP).

TargeGen has received financial backing to date from first tier investors including Forward Ventures (San Diego), Enterprise Partners (La Jolla) and other investors.

For additional information, contact:

Peter G. Ulrich, President & CEO
TargeGen, Inc.
9393 Towne Centre Drive
Suite 120
San Diego, CA 92121
Tel 858-678-0760
Fax 858-678-0762
ulrich@targegen.com
http://www.targegen.com